Successful use of trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive Gastric Cancer

Anticancer Research

Volumn 34, Issue 1, 2014, Pages 301-306

  Palacio, Sofia ^a   Loaiza Bonilla, Arturo ^b   Kittaneh, Muaiad ^c   Kyriakopoulos, Christos ^d   Ochoa, Roberto E ^e   Escobar, Mauricio ^a   Arango, Belisario ^a   Restrepo, Maria H ^a   Merchan, Jaime R ^a   Lima, Caio M S Rocha ^a   Hosein, Peter J ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d TAUSSIG CANCER INSTITUTE   (United States)

^e Chen Medical Centers   (United States)

Author keywords

Chemotherapy; Gastric cancer; Trastuzumab

Indexed keywords

CAPECITABINE; CARVEDILOL; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; TRASTUZUMAB; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; BONE METASTASIS; BRADYCARDIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG TOLERANCE; DYSPHAGIA; ELECTROCARDIOGRAM; ESOPHAGOGASTRODUODENOSCOPY; ESOPHAGUS RESECTION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART EJECTION FRACTION; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERTRANSAMINASEMIA; INDUCTION CHEMOTHERAPY; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAINTENANCE CHEMOTHERAPY; MALE; MEDIASTINUM METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NECK TUMOR; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIAL GASTRECTOMY; PERCUTANEOUS BIOPSY; PERIPHERAL NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; STOMACH ADENOCARCINOMA; STOMACH BIOPSY; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; CANCER STAGING; CASE REPORT; CHEMOTHERAPY; COMPARATIVE STUDY; FOLLOW UP; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; STOMACH TUMOR;

CHEMOTHERAPY; GASTRIC CANCER; TRASTUZUMAB;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; EPIRUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS;

EID: 84897022909     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-917, 2010.
2. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
3. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24: 4991-4997, 2006.
4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001.
5. Arteaga CL: Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer. Breast Cancer Res 5: 96-100, 2003.
6. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL et al: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer J Clin Oncol 23: 3676-3685, 2005.
7. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA et al: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127, 2004.
8. Hegewisch-Becker S, Moorahrend E, Kröning H, Petersen V, Hannig C, Pott D et al: Trastuzumab (TRA) in combination with different first-line chemotherapies for treatment of HER2-positive metastatic gastric or gastroesophageal junction cancer (MGC): Findings from the German noninterventional observational study HerMES. J Clin Oncol 30(Suppl): 4065, 2012.
9. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 28;376: 687-697, 2010.
10. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11-20, 2006.
11. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F et al: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358: 36-46, 2008.
12. Dhesy-Thind B, Pritchard KI, Messersmith H, O'Malley F, Elavathil L and Trudeau M: HER2/neu in systemic therapy for women with breast cancer: a systematic review. Breast Cancer Res Treat 109: 209-229, 2008.
13. Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U et al: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 100: 14-20, 2008.
14. Jarvinen TA, Holli K, Kuukasjarvi T and Isola JJ: Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 77: 2267-2273, 1998.
15. Bartlett JM, Munro A, Cameron DA, Thomas J, Prescott R and Twelves CJ: Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J Clin Oncol 26: 5027-5035, 2008.
16. Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A et al: Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol 29: 859-867, 2011.
17. Untch M, Muscholl M, Tjulandin S, Jonat W, Meerpohl HG, Lichinitser M et al: First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. J Clin Oncol 28: 1473-1480, 2010.
18. Fumoleau P, Roche H, Kerbrat P, Bonneterre J, Romestaing P, Fargeot P et al: Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol 17: 85-92, 2006.
19. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 4. National Cancer Institute; 2010 [cited 2013 12/01/2013]; Available from: http://evs.nci.nih.gov/ftp1/CTCAE/About.html.
20. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM et al: 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382: 1021-1028, 2013.
21. Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M et al: OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 24(3): 394-400, 2006.